Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients. (PRE-EVE)

Centre Hospitalier Universitaire de Saint Etienne

Status: Completed

Conditions: Preeclampsia

Treatments: Biological: Placenta pathological examination

Study type: Observational

Funder types: Other

Identifiers

NCT04846686

IRBN622021/CHUSTE

Details and patient eligibility

About

The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors.

A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.

Enrollment: 35 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
• For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
• For the control group: patient who had a normal pregnancy

Exclusion criteria

• Patient who gave birth naturally
• Underage patients or under guardianship
• Patients who do not speak or read French
• Childbirth under X

Trial design

35 participants in 2 patient groups

preeclampsia group

Description:

25 patients with a diagnostic of preeclampsia, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with programme for medicalization of information systems (PMSI) will be realized. Placenta pathological examination will be performed.

Treatment:

Biological: Placenta pathological examination

control group

Description:

10 patients who had a normal pregnancy, having undergone a placental pathological examination and having given birth by cesarean section. A cross-referencing of data with PMSI will be realized. Placenta pathological examination will be performed.

Treatment:

Biological: Placenta pathological examination